Loading...
•
Mar 31, 2020
Heron Therapeutics Q1 2020 Earnings Report
Heron Therapeutics reported a net loss of $51.6 million and net product sales of $25.4 million for the three months ended March 31, 2020.
Key Takeaways
Heron Therapeutics reported a net loss of $51.6 million, or $0.57 per share, for the three months ended March 31, 2020. Net product sales for the same period were $25.4 million. The company's cash, cash equivalents, and short-term investments totaled $356.3 million as of March 31, 2020, which is expected to fund operations into 2022.
Heron anticipates a decision by Health Canada on the New Drug Submission for HTX-011 in the third quarter of 2020.
The FDA indicated they continue on schedule with their review of the NDA for HTX-011, with a PDUFA date of June 26, 2020.
CINV franchise net product sales were $25.4 million for the three months ended March 31, 2020.
Heron expects 2020 net product sales for the CINV franchise of $70 million to $80 million.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.com Forward Guidance
Heron expects 2020 net product sales for the CINV franchise of $70 million to $80 million and the CINV franchise to return to growth in 2021 and beyond.